Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis
about
Viruses as co-factors for the initiation or exacerbation of lung fibrosisAntileukotriene agents for the treatment of lung disease5-lipoxygenase mRNA and protein isoformsRapid import of cytosolic 5-lipoxygenase into the nucleus of neutrophils after in vivo recruitment and in vitro adherenceCyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in miceCapacity for repeatable leukotriene generation after transient stimulation of mast cells and macrophagesNuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lungInvolvement of cAMP-response element binding protein-1 in arachidonic acid-induced vascular smooth muscle cell motilityCharacterization of interleukin-4-stimulated nasal polyp fibroblasts.Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.Toward functional proteomics of alveolar macrophages.Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection.Leukotriene B4, administered via intracerebroventricular injection, attenuates the antigen-induced asthmatic response in sensitized guinea pigsFollowing the path of CCL2 from prostaglandins to periostin in lung fibrosisIntracellular compartmentalization of leukotriene biosynthesis.Claude H. Organ, Jr. memorial lecture: splanchnic hypoperfusion provokes acute lung injury via a 5-lipoxygenase-dependent mechanism.Novel therapeutic approaches for pulmonary fibrosis.Integrating mechanisms of pulmonary fibrosisProstaglandin E2 and the pathogenesis of pulmonary fibrosis.Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host diseaseDisorders of lung matrix remodeling.Epithelial-mesenchymal interactions in pulmonary fibrosis.Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapyFluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function.Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis.Collagenase-3 induction in rat lung fibroblasts requires the combined effects of tumor necrosis factor-alpha and 12-lipoxygenase metabolites: a model of macrophage-induced, fibroblast-driven extracellular matrix remodeling during inflammatory lung iEicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?Current and emerging drugs for idiopathic pulmonary fibrosis.TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis.Inflammation and cancer: how friendly is the relationship for cancer patients?Determinants of initiation and progression of idiopathic pulmonary fibrosis.How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantationFluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patientsInvestigational approaches to therapies for idiopathic pulmonary fibrosis.Opposing roles of leukotrienes and prostaglandins in fibrotic lung disease.Viral infection and aging as cofactors for the development of pulmonary fibrosis.Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation.Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.Targeted therapies for systemic sclerosis.
P2860
Q27487313-D83B1ACB-4353-4373-8B70-C1CF4C7392E0Q28293842-FD02ABC7-BF7B-4E43-BF46-AA11321D2DDFQ28298153-672F61EF-4F0E-4DD6-8A5F-F56AC8828FF4Q28306480-7142878B-2D7A-40A6-8BA0-6B036F806877Q28362073-6699C429-B267-4556-983F-63CF5F75F117Q28379311-2F47471F-03CD-4774-AA42-0EE5C0783013Q28565050-606B2062-6853-4083-954D-D04065B3AAF6Q28582121-5847CBEB-E3E5-4071-A41E-4E1B4762F87BQ30311131-CEB3D4A5-CFF0-4485-AF3E-F757B312F490Q30837023-A211CC7C-4171-436E-8767-A8FEFA6C2BF7Q31152540-C08CAB97-18E8-4594-870C-492B6D200459Q33595066-70449342-18A5-4391-BC84-4EC74A4A3D93Q33711782-3D1F3095-E29C-45CA-B0E7-3F45D4B02CEEQ33799756-A8EEBD86-E431-44EE-8061-8438BE9F062FQ33836695-45F9930B-EF61-4DE1-B05B-900F00ABB588Q34540293-462F7311-9474-4491-B0C5-6BEC2C318DEBQ34903224-C9B5A342-0A84-4056-8464-6273B3B554DEQ35106452-AB6650CC-9824-4A1A-AD96-42A253DFF2BDQ35219865-4CC06D74-1CB3-4D4F-B334-54D26C0FDEE0Q35293711-7199AC7C-6294-49CF-A525-B30CCD933883Q35628568-EB333777-A8E1-40AF-92F2-1DE4B08A0268Q36427136-C56B596F-5937-4ABF-980D-15C5BE3D3BA0Q36440438-DEB6DB73-DBB0-450F-8493-F5F3948D4019Q36712018-5BA8DE66-B774-4E9A-9810-748634FFA34EQ36822323-0868D5D9-C2AB-4D2F-834A-12EBA75F6070Q36853612-B132F91F-0E7D-4EBB-9827-9A7DF2926D62Q36875294-AF7CBE9F-E753-4780-A198-0EFE50E85F75Q36970702-B2553531-F58D-424A-8F79-960DDF06B58BQ36989934-07A7FB5A-D04A-4BF6-8500-7DF2EF1927E3Q37101056-C110C518-28E7-46D2-AA06-F96AA3F599CCQ37316105-9CD623D7-6E4D-4799-936A-29C03950DAEEQ37594222-34899988-6A7E-4893-BC2B-4A17B9CCC717Q37609903-E029C044-9883-466F-BD1B-185F03171BCDQ37703430-0BE8F47A-7616-4C57-B575-215DA76D3B19Q37742646-E413F139-0069-4AF2-84D4-6B6B14EE0D9CQ37754750-61E101D4-EFC6-4C19-BA21-2BAA46894C43Q37815487-D79AE80F-56FE-407E-AF0C-47326B7A1A9AQ37846706-FC696015-41B5-496F-8406-63DDC73CC25FQ37858415-22F41F04-B1BF-47D4-B74C-C930521054EEQ38097276-178E3383-6DE7-4733-9222-7F2AEF3426C6
P2860
Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Constitutive activation of 5-l ...... idiopathic pulmonary fibrosis
@en
Constitutive activation of 5-l ...... idiopathic pulmonary fibrosis.
@nl
type
label
Constitutive activation of 5-l ...... idiopathic pulmonary fibrosis
@en
Constitutive activation of 5-l ...... idiopathic pulmonary fibrosis.
@nl
prefLabel
Constitutive activation of 5-l ...... idiopathic pulmonary fibrosis
@en
Constitutive activation of 5-l ...... idiopathic pulmonary fibrosis.
@nl
P2093
P2860
P356
P1476
Constitutive activation of 5-l ...... idiopathic pulmonary fibrosis
@en
P2093
M Peters-Golden
R Strieter
P2860
P304
P356
10.1172/JCI118612
P407
P577
1996-04-01T00:00:00Z